Transplantation of solid organs and cellular grafts has become clinical routine in the last 30 years. However, the requirement for life-long immunosuppression is associated with infections, malignancies and end-organ toxicity. Moreover, the treatment fails to prevent chronic rejection. The induction of donor-specific transplantation tolerance would solve these problems, but has remained an elusive goal. One approach to achieve transplantation tolerance is through hematopoietic chimerism. This review outlines different concepts of hematopoietic chimerism focusing on macrochimerism. Mixed allogeneic chimerism, also known as macrochimerism, is defined as engraftment of hematopoietic stem cells achieved by bone marrow transplantation (BMT). It discusses the advantages and limitations of the BMT as well as approaches to overcome these limitations in the future.

Keywords:
Bone marrow transplantation, Facilitating cell, Mixed allogeneic chimerism, Tolerance
1.
Nagano H, Tilney NL: Chronic allograft failure: The clinical problem. Am J Med Sci 1997;313:305.
2.
Billingham RE, Medawar PB: The technique of free skin grafting in mammals. J Exp Biol 1951;28:385.
3.
Billingham RE, Lamphin HG, Medawar PB, Williams HL: Tolerance of homografts, twin diagnosis and the freemartin conditions in cattle. Heredity 1952;6:201.
4.
Owen RD: Immunogenic consequences of vascular anastomoses between bovine twins. Science 1945;102:400.
5.
Billingham RE, Brent L, Medawar PB: Actively acquired tolerance of foreign cells. Nature 1953;172:603.
6.
George JF, Sweeney SD, Kirklin JK, Simpson EM, Goldstein DR, Thomas JM: An essential role for Fas ligand in transplantation tolerance induced by donor bone marrow. Nat Med 1998;4:333.
7.
Bemelman F, Honey K, Adams E, Cobbold S, Waldmann H: Bone marrow transplantation induces either clonal deletion or infectious tolerance depending on the dose. J Immunol 1998;160:2645.
8.
Starzl TE, Demetris AJ, Murase N, Ildstad ST, Ricordi C, Trucco M: Cell migration, chimerism and graft acceptance. Lancet 1992;339:1579.
9.
Knobler HY, Sagher U, Peled IJ, Wexler MR, Steiner D, Rubinstein N, Weshler Z, Or R, Slavin S: Tolerance to donor-type skin in the recipient of a bone marrow allograft. Treatment of skin ulcers in chronic graft-versus-host disease with skin grafts from the bone marrow donor. Transplantation 1985;40:223.
10.
Sayegh MH, Fine NA, Smith JL, Rehnke HG, Milford EL, Tilney NL: Immunologic tolerance to renal allografts after bone marrow transplants from the same donors. Ann Intern Med 1991;114:954.
11.
Billingham RE: Reactions of grafts against their hosts: Transplantation immunity works both ways – Hosts destroy grafts and grafts may harm hosts. Science 1959;3381:947.
12.
Lampert IA, Janossy G, Suitters AJ, Bofill M, Palmer S, Gordon-Smith E, Prentice HG, Thomas JA: Immunological analysis of the skin in graft versus host disease. Clin Exp Immunol 1982;50:123.
13.
Snover DC: Graft-versus-host disease of the gastrointestinal tract. Am J Surg Pathol 1990;14(suppl 1):101–108.
14.
Beschorner WE, Pino J, Boitnott JK, Tutschka PJ, Santos GW: Pathology of the liver with bone marrow transplantation. Effects of busulfan, carmustine, acute graft-versus-host disease, and cytomegalovirus infection. Am J Pathol 1980;99:369.
15.
Deeg HJ, Storb R, Thomas ED: Bone marrow transplantation: A review of delayed complications. Br J Haematol 1984;57:185.
16.
Vettenranta K, Hovi L, Parto K, Saarinen-Pihkala UM: Very low-dose methotrexate in the treatment of GVHD in children. Bone Marrow Transplant 1997;20:75.
17.
Blazar BR, Taylor PA, Fitzsimmons WE, Vallera DA: FK506 inhibits graft-versus-host disease and bone marrow graft rejection in murine recipients of MHC disparate donor grafts by interfering with mature peripheral T cell expansion post-transplantation. J Immunol 1994;153:1836.
18.
Blazar BR, Korngold R, Vallera DA: Recent advances in graft-versus-host disease (GVHD) prevention. Immunol Rev 1997;157:79–109.
19.
Korngold B, Sprent J: Lethal graft-versus-host disease after bone marrow transplantation across minor histocompatibility barriers in mice. Prevention by removing mature T cells from marrow. J Exp Med 1978;148:1687.
20.
Martin PJ, Hansen JA, Torok-Storb B, Durnam D, Przepiorka D, O’Quigley J, Sanders J, Sullivan KM, Witherspoon RP, Deeg HJ, et al: Graft failure in patients receiving T cell-depleted HLA-identical allogeneic marrow transplants. Bone Marrow Transplant 1988;3:445.
21.
Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ildstad ST: Phenotypic characterization of a novel bone marrow-derived cell that facilitates engraftment of allogeneic bone marrow. Blood 1994;84:2436.
22.
Ildstad ST, Crilley PA, Shadduck RA, Kaufman CL, Mirrow J, Brodsky I, Brugger W, Gajewski JL, Przepiorka D, Styler MJ, Lister J, Topolsky DL, Manz M, Kanz L, Champlin RL: Graft engineering: The facilitating cell (FC) protocol in HLA mismatched BMT for hematologic malignancy. Blood 1997;90:484.
23.
Wood ML, Monaco AP, Gozzo JJ, Liegeois A: Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: Dose and timing. Transplant Proc 1971;3:676.
24.
McCarthy SA, Griffith IJ, Gambel P, Francescutti LH, Wegmann TG: Characterization of host lymphoid cells in antibody-facilitated bone marrow chimeras. Transplantation 1985;40:12.
25.
Cobbold SP, Martin G, Qin S, Waldmann H: Monoclonal antibodies to promote marrow engraftment and tissue graft tolerance. Nature 1986;323:164.
26.
Mayumi H, Good RA: The necessity of both allogeneic antigens and stem cells for cyclophosphamide-induced skin allograft tolerance in mice. Transplant Proc 1988;20:139.
27.
Storb R, Yu C, Wagner JL, Deeg HJ, Nash RA, Kiem HP, Leisenring W, Shulman H: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997;89:3048.
28.
Sykes M, Szot GL, Swenson KA, Pearson DA: Induction of high levels of allogeneic hematopoietic reconstitution and donor-specific tolerance without myelosuppressive conditioning. Nat Med 1997;3:783.
29.
Colson YL, Li H, Boggs SS, Patrene KD, Johnson PC, Ildstad ST: Durable mixed chimerism and tolerance by a non-lethal radiation-based cytoreductive approach. J Immunol 1996;157:2820.
30.
Exner BG, Colson YL, Li H, Ildstad ST: In vivo depletion of host CD4+ and CD8+ cells permits engraftment of bone marrow stem cells and tolerance induction with minimal conditioning. Surgery 1997;122:221.
1999
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.